Opalia cultivates mammary cells in bioreactors to produce complete milk—including proteins, fats, and sugars—intended as a drop-in replacement for conventional fluid or powdered milk. The company positions its approach as distinct from precision fermentation by producing whole milk rather than single milk proteins. Opalia targets the global dairy market through a B2B licensing and supply model rather than direct-to-consumer sales. It has signed paid commercial pilot agreements with established dairy players, including Hoogwegt and the Canadian division of a major dairy group, with partnerships across five countries on three continents. Opalia plans to scale a modular bioreactor system using proceeds from the CAD 3.2M seed round and aims for a commercial launch in 2028 while pursuing regulatory approvals in North America, Europe, and Asia.

Total raised

$5M

Funding rounds

3

Latest round

Equity

Latest activity

Apr 2026